期刊
ORGANIC PROCESS RESEARCH & DEVELOPMENT
卷 14, 期 4, 页码 946-959出版社
AMER CHEMICAL SOC
DOI: 10.1021/op900341a
关键词
-
Recent guidelines from drug regulatory authorities in Europe and the Untited States of America (USA) require the control of genotoxic and potentially genotoxic impurities at parts per million levels in drug substances. This review will discuss the background to the guidelines and the various strategies drug substance manufacturers have employed to comply with the very tight constraints. These strategies include (a) redesigning the drug substance synthesis to avoid introducing problematic impurities, GO altering relevant process parameters to remove or reduce such impurities to insignificant levels, (c) deploying process understanding to prove that a particular genotoxic impurity either cannot be formed or will be efficiently removed, (d) conducting toxicity studies to demonstrate that a suspect impurity is not harmful at the low levels envisaged for it. Examples of each approach are given.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据